Ultomiris

Alexion's new blockbuster Ultomiris keeps gaining steam as $39B AstraZeneca deal looms
Alexion's new blockbuster Ultomiris keeps gaining steam as $39B AstraZeneca deal looms
Fierce Pharma
AstraZeneca
Alexion
Ultomiris
Flag link:
Alexion touts new PhIII data of Soliris successor as planned AstraZeneca takeover looms
Alexion touts new PhIII data of Soliris successor as planned AstraZeneca takeover looms
Endpoints
Alexion
AstraZeneca
M&A
clinical trials
Ultomiris
myasthenia gravis
Flag link:
Key third-quarter readouts for big pharma
Key third-quarter readouts for big pharma
EP Vantage
clinical trials
Pfizer
Roche
idanacogene elaparvovec
Alexion
AstraZeneca
Ultomiris
AbbVie
Rinvoq
Novartis
sabatolimab
Flag link:
Alexion trials rare disease drug Ultomiris in severe COVID-19 cases
Alexion trials rare disease drug Ultomiris in severe COVID-19 cases
Pharmaforum
Alexion
Ultomiris
COVID-19
Flag link:
Alexion to start Phase III study of blood disorder drug in Covid-19 respiratory disease
Alexion to start Phase III study of blood disorder drug in Covid-19 respiratory disease
MedCity News
Alexion
COVID-19
Ultomiris
clinical trials
Flag link:
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
Yahoo/Zacks.com
Alexion
ALS
Ultomiris
clinical trials
Flag link:
Roche's Chugai claims Alexion co-opted its patented tech in building Ultomiris
Roche's Chugai claims Alexion co-opted its patented tech in building Ultomiris
Fierce Pharma
Alexion
Chugai
Roche
Ultomiris
patents
Flag link:
FDA approves Alexion's Ultomiris for another rare blood disease
FDA approves Alexion's Ultomiris for another rare blood disease
Yahoo/Reuters
Alexion
FDA
Ultomiris
aHUS
Flag link:
Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?
Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?
Fierce Pharma
Alexion
Soliris
Ultomiris
PNH
Flag link:
Alexion’s Soliris follow-up Ultomiris snares EU approval
Alexion’s Soliris follow-up Ultomiris snares EU approval
Pharmaforum
Alexion
Europe
Ultomiris
Soliris
patents
PNH
Flag link:
FDA fast-tracks Alexion's Ultomiris in 2nd Soliris indication
FDA fast-tracks Alexion's Ultomiris in 2nd Soliris indication
Fierce Pharma
Alexion
Ultomiris
FDA
atypical hemolytic uremic syndrome
Flag link:
Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria
Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria
Pharmaceutical Business Review
Alexion Pharmaceuticals
Ultomiris
PNH
Flag link:
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
Motley Fool
Alexion
Ultomiris
AbbVie
Upadacitinib
risankizumab
Aimmune Therapeutics
AR-101
Bluebird Bio
LentiGlobin
Flag link:
Alexion gets off to the races with key Ultomiris, Soliris launches
Alexion gets off to the races with key Ultomiris, Soliris launches
Fierce Pharma
Alexion
Ultomiris
Soliris
drug launches
Flag link:
4 Blockbuster Drug Launches to Watch in 2019
4 Blockbuster Drug Launches to Watch in 2019
Motley Fool
drug launches
AbbVie
Alexion Pharmaceuticals
Aimmune Therapeutics
Skyrizi
psoriasis
Upadacitinib
rheumatoid arthritis
Ultomiris
PNH
AR101
peanut allergy
Flag link:
Alexion runs toward big Ultomiris goals with early Soliris switching success
Alexion runs toward big Ultomiris goals with early Soliris switching success
Fierce Pharma
Alexion
Ultomiris
paroxysmal nocturnal hemoglobinuria
PNH
Flag link:
Alexion’s newly approved rare-disease drug notches another clinical trial win
Alexion’s newly approved rare-disease drug notches another clinical trial win
Stat
Alexion Pharmaceuticals
clinical trials
Ultomiris
kidney disease
PNH
Flag link:
FDA approves new Alexion’s therapy targeting paroxysmal nocturnal hemoglobinuria
FDA approves new Alexion’s therapy targeting paroxysmal nocturnal hemoglobinuria
GoinPharma
Alexion
FDA
ALXN1210
Ultomiris
PNH
Flag link:
Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris
Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris
Stat
Alexion Pharmaceuticals
FDA
Ultomiris
Soliris
PNH
Flag link: